These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

682 related items for PubMed ID: 16716150

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Rituximab in treatment-resistant autoimmune blistering skin disorders.
    Schmidt E, Bröcker EB, Goebeler M.
    Clin Rev Allergy Immunol; 2008 Feb; 34(1):56-64. PubMed ID: 18270859
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Epidermolysis bullosa acquisita following bullous pemphigoid, successfully treated with the anti-CD20 monoclonal antibody rituximab.
    Wallet-Faber N, Franck N, Batteux F, Mateus C, Gilbert D, Carlotti A, Avril MF, Dupin N.
    Dermatology; 2007 Feb; 215(3):252-5. PubMed ID: 17823525
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Successful treatment of refractory childhood pemphgus vulgaris with anti-CD20 monoclonal antibody (rituximab).
    Kong HH, Prose NS, Ware RE, Hall RP.
    Pediatr Dermatol; 2005 Feb; 22(5):461-4. PubMed ID: 16191003
    [Abstract] [Full Text] [Related]

  • 11. Rituximab in autoimmune bullous diseases: mixed responses and adverse effects.
    Schmidt E, Seitz CS, Benoit S, Bröcker EB, Goebeler M.
    Br J Dermatol; 2007 Feb; 156(2):352-6. PubMed ID: 17223877
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Rituximab in dermatological diseases.
    Troiano M, Lotti T.
    G Ital Dermatol Venereol; 2009 Aug; 144(4):495-9. PubMed ID: 19755955
    [Abstract] [Full Text] [Related]

  • 14. Two courses of rituximab (anti-CD20 monoclonal antibody) for recalcitrant pemphigus vulgaris.
    Faurschou A, Gniadecki R.
    Int J Dermatol; 2008 Mar; 47(3):292-4. PubMed ID: 18289336
    [Abstract] [Full Text] [Related]

  • 15. [Efficacy of rituximab in a case of refractory bullous pemphigoid].
    Reguiaï Z, Tchen T, Perceau G, Bernard P.
    Ann Dermatol Venereol; 2009 May; 136(5):431-4. PubMed ID: 19442800
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Treatment of severe autoimmune blistering skin diseases with combination of protein A immunoadsorption and rituximab: a protocol without initial high dose or pulse steroid medication.
    Kolesnik M, Becker E, Reinhold D, Ambach A, Heim MU, Gollnick H, Bonnekoh B.
    J Eur Acad Dermatol Venereol; 2014 Jun; 28(6):771-80. PubMed ID: 23651052
    [Abstract] [Full Text] [Related]

  • 18. Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab).
    Marzano AV, Fanoni D, Venegoni L, Berti E, Caputo R.
    Dermatology; 2007 Jun; 214(4):310-8. PubMed ID: 17460402
    [Abstract] [Full Text] [Related]

  • 19. Rituximab in severe pemphigus.
    Schmidt E, Goebeler M, Zillikens D.
    Ann N Y Acad Sci; 2009 Sep; 1173():683-91. PubMed ID: 19758216
    [Abstract] [Full Text] [Related]

  • 20. The efficacy and safety of rituximab in refractory pemphigus: a review of case reports.
    Allen KJ, Wolverton SE.
    J Drugs Dermatol; 2007 Sep; 6(9):883-9. PubMed ID: 17941359
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.